Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.24M Sell
92,920
-7,509
-7% -$196K 1.44% 16
2026
Q1
$2.82M Sell
100,429
-42,351
-30% -$1.13M 1.83% 7
2025
Q4
$3.56M Buy
+142,780
New +$3.6M 2.22% 7

Other funds holding PFE

Rare Wolf Capital's PFE Position: Q2 2026 in Review

Rare Wolf Capital reduced its Pfizer (PFE) stake by 7.5% in Q2 2026, selling an estimated $196K and leaving 92,920 shares worth $2.24M. The position accounts for 1.44% of the portfolio, ranked #16.

Rare Wolf Capital first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.56M in Q4 2025. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Rare Wolf Capital held 92,920 shares of Pfizer worth $2.24M as of Q2 2026.
  • Rare Wolf Capital sold 7,509 Pfizer shares in Q2 2026, an estimated $196K.
  • Pfizer made up 1.44% of Rare Wolf Capital's portfolio in Q2 2026, its #16 holding.
  • Rare Wolf Capital first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • Rare Wolf Capital's Pfizer position peaked at $3.56M in Q4 2025.
  • 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Rare Wolf Capital's 13F filing for Q2 2026, filed 24 Jul 2026.